| Previous Close | 0.66 |
| Open | 0.69 |
| Bid | 0.63 x 0 |
| Ask | 0.69 x 0 |
| Day's Range | 0.69 - 0.69 |
| 52 Week Range | 0.60 - 1.10 |
| Volume | 500 |
| Avg. Volume | 5,034 |
| Market Cap | 71.672M |
| Beta (3Y Monthly) | -0.09 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.09 |
| Earnings Date | Jun 11, 2018 - Jun 15, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Helix BioPharma Corp. (TSX, FSE: HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has received conditional approval from the Toronto Stock Exchange (the “TSX”) to extend the exercise period of a total of 4,546,000 outstanding common share purchase warrants (the “Warrants”), all of which are held by arm’s length parties. The Warrants were issued pursuant to a private placement of the Company completed on November 1, 2013, and represent approximately 4.4% of the Company’s issued and outstanding common shares.
Helix BioPharma Corp. (HBP.TO), (HBP.F) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has extended its collaboration agreement with Moffitt Cancer Center for an additional year. Preliminary studies in this model showed that L-DOS47 may increase the activity of a PD-1/PD-L1 inhibitor in treating pancreatic cancer. Analysis of the immune response that is occurring in the tumor upon L-DOS47 combination treatment will also be characterised.
Helix BioPharma Corp. (TSX, FSE: HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Safety Review Committee ("SRC") reviewed safety data from the fifth dosing cohort of the Company’s LDOS001 study and recommended that Helix begin enrollment of patients into the sixth dosing cohort. LDOS001 is a dose escalation study of L-DOS47 with pemetrexed and carboplatin in recurrent or metastatic non-squamous non-small cell lung cancer. “The Company has made good progress in advancing this trial, the FDA approved amendment helped to accelerate dose escalation and the completion of the last two cohorts will provide additional important clinical data,” said Heman Chao, Helix's Chief Executive Officer.
Helix BioPharma Corp. (HBP.TO), (HBP.F) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that its collaborator ProMab Biotechnologies, Inc. (“ProMab”) paper entitled ‘CAR-T cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth’ is published in Cancers – an open access journal (http://www.mdpi.com/journal/cancers). “I want to congratulate the ProMab team for publishing the excellent work they have conducted on this antibody,” said Heman Chao, Helix’s Chief Executive Officer. Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy.
Helix BioPharma Corp. (HBP.TO)(HBP.F) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for gross proceeds of CAD456,000. Each unit is comprised of one common share and one common share purchase warrant. Each common share purchase warrant will entitle the holder to purchase one common share at an exercise price of $1.50 and have an expiry of five years from the date of issuance. Helix intends to use the net proceeds of the private placement for working capital and research and development activities.
Helix BioPharma Corp. (HBP.TO), (HBP.F) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that its collaborator ProMab Biotechnologies, Inc. (“ProMab”) will present at the CAR-TCR Summit 2018 being held from September 4th - 7th, 2018 in Boston, Massachusetts. Dr. Vita Golubovskaya, Director, R&D, BD of Promab Biotechnologies will present on September 5th at 12:25pm. The title of the presentation is “Novel CAR-T Cells Against Solid and Hematological Cancers”. Dr. Golubovskaya’s presentation will include certain preclinical data from the multiple myeloma project currently in collaboration with Helix. To achieve this goal, Helix’s wholly-owned Polish subsidiary Helix Immuno-Oncology (“HIO”) will be leading the preclinical and clinical development program in Poland prioritizing a possible European clinical submission.
Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for gross proceeds of CAD818,400. Each unit is comprised of one common share and one common share purchase warrant. Each common share purchase warrant will entitle the holder to purchase one common share at an exercise price of $1.50 and have an expiry of five years from the date of issuance. Helix intends to use the net proceeds of the private placement for working capital and research and development activities.
Helix BioPharma Corp. (HBP.TO) (HBP.F) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Safety Review Committee ("SRC") reviewed safety data from the fourth dosing cohort of the Company’s LDOS001 study and recommended that Helix begin enrollment of patients into the fifth dosing cohort. LDOS001 is a dose escalation study of L-DOS47 with pemetrexed and carboplatin in recurrent or metastatic non-squamous non-small cell lung cancer.
NEW YORK, NY / ACCESSWIRE / February 23, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...
Helix BioPharma Corp. , a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that together with its...
Helix BioPharma Corp. , an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has been selected to present at the...
Helix BioPharma Corp. , an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the finalization of a collaborative binding...
Helix BioPharma Corp. , an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for...
Helix BioPharma Corp. , an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the first quarter of fiscal 2018 ending ...
Helix BioPharma Corp. , an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, announced today the results of matters voted on at its annual and special meeting ...